ピオグリダゾン
Conclusion: Pioglitazone is a safe medication that has a promising effect in slowing the advancement of AD.
Various GLP-1RAs have been demonstrated to have significant benefits in in vitro and in vivo models of neurodegenerative diseases through modulating a variety of pathogenic mechanisms, including neuroinflammation, autophagy, mitochondrial dysfunction, and the abnormal phosphorylation of pathognomonic protei
These agents also have substantial protective effects on cognitive and behavioral functions, such as motor function. However, clinical trials investigating GLP-1RAs in diseases such as AD, PD, mild cognitive impairment, psychiatric disorders, and diabetes have yielded mixed results for cognitive and motor function.
Five hundred twenty-five records were obtained, from which five studies were included for quantitative analysis
Data was extracted using a pretested form, which was followed by a risk of bias assessment (ROB) with Cochrane's ROB assessment tool.
Data was extracted using a pretested form, which was followed by a risk of bias assessment (ROB) with Cochrane's ROB assessment tool.
2024年12月18日 | カテゴリー：各種治療学, 各種病因学, 癌の病態生理と治療学, 循環器, 糖尿病 |
